期刊文献+

HPLC法测定草酸阿德福韦酯片溶出度

Deter mination of dissolution of Adefovir Dipivoxil Oxalic Acid tablets by HPLC
下载PDF
导出
摘要 目的采用高效液相色谱法测定草酸阿德福韦酯片的溶出度。方法按照中国药典2010年版二部溶出度测定法中的第二法,以0.1mol/L HCl600mL为溶出介质,转速为50rpm,45min时采样,以高效液相色谱法测定。色谱柱:DiamonsilC18(150mm×4.6mm,5μm);流动相:甲醇-水-冰醋酸=50:50:0.1;流速:1.0mL/min;检测波长:258nm,以外标法测定草酸阿德福韦酯片的溶出度。结果线性范围为9.42~22.62μg/mL。平均回收率为100.2%。(RSD为0.50%,n=9),溶出度符合规定。结论该方法简便、易行,结果准确。 Objective The research establish HPLC methods for dissolution of Adefovir Dipivoxil Oxalic Acid tablets.M ethods Perform the test according to apparatus II,the medium is 0.01mol/L hydrochloric acid,600ml,50rpm.The dissolution time is 45min.Use HPLC method for the determination.Diamonsil C18 column(150mm ×4.6mm,5μm) is used with methanol,water and glacial acetic acid(50:50:0.1) as the mobile phase,with flow rate of 1.0mL/min and the detection wavelength of 258nm.Results The linear range of Adefovir Dipivoxil is 9.42~22.62 μg/mL,the average recovery is 100.2% and the RSD is 0.50%.C onclusion The method is convenient,sensitive and accurate for the determination of the drug.
作者 王喜军 杨蕾
出处 《中外医疗》 2013年第17期18-19,共2页 China & Foreign Medical Treatment
关键词 草酸阿德福韦酯片 溶出度 高效液相色谱法 Adefovir Dipivoxil Oxalic Acid tablets Dissolution HPLC method
  • 相关文献

参考文献5

  • 1Ganem D,Prince AM.Hepatitis B virus infection-natural history andclnicalconsequences[J].N Engl J Med,2004,350:1118-1119.
  • 2代洁(综述),唐红(审校).阿德福韦酯耐药分子机制研究[J].生物医学工程学杂志,2012,29(1):184-187. 被引量:4
  • 3Almeida AM,Ribeiro AQ,Padua CA,et al.The efficacy of adefovir dip-ivoxil,entecavir and telbivudine for chronic hepatitis B treatment:a sys-tematic review[J].Rev Soc Bras Mad Trop,2010,43(4):440-451.
  • 4Song BC,Cui XJ,Shin JW,et al.Response to adefovir depends on mu-tation patterns in precore region,basal core promoter and reverse tran-scriptase,and on-treatment responses in lamivudine-resistant chronichepatitis B patients[J].Intervirology,2010,53(4):203-210.
  • 5Strasfeld L,Chou SW.Antiviral drug resistance:mechanisms and clini-cal implications[J].Infect Dis Clin North Am,2010,24(3):809-833.

二级参考文献29

  • 1王春亚,钟彦伟,杨昊臻,刘杰,刘斌.HBV逆转录酶区N236T突变与A181T突变患者临床特征的比较[J].实用医院临床杂志,2010,7(4):47-48. 被引量:5
  • 2秦艳丽,张继明,黄玉仙,毛日成,尹有宽,章婉琴,张清波,邬祥惠,翁心华.阿德福韦治疗拉米夫定耐药慢性乙型肝炎患者的耐药率及耐药株进化情况[J].中华肝脏病杂志,2007,15(1):4-7. 被引量:56
  • 3GANEM D,PRINCE A M.Hepatitis B virus infection-natu-ral history and clinicalconsequences[J].N Engl J Med,2004,350:1118-1119.
  • 4LEUNG N.Recent data on treatment of chronic hepatitis Bwith nucleos(t)ide analogues[J].Hepatol Int,2008,2(2):163-178.
  • 5ALMEIDA A M,RIBEIRO A Q,PDUA C A,et al.Theefficacy of adefovir dipivoxil,entecavir and telbivudine forchronic hepatitis B treatment:a systematic review[J].RevSoc Bras Med Trop,2010,43(4):440-451.
  • 6KIM H J,PARK J H,PARK D I,et al.Rescue therapy forlamivudine-resistant chronic hepatitis B:comparison betweenentecavir 1.0 mg monotherapy,adefovir monotherapy andadefovir add-on lamivudine combination therapy[J].J Gastro-enterol Hepatol,2010,25(8):1374-1380.
  • 7KARAYIANNIS P.Hepatitis B virus:old,new and future ap-proaches to antiviral treatment[J].J Antimicrob Chemother,2003,51(4):761-785.
  • 8ZOULIM F.Antiviral therapy of chronic hepatitis B:can weclear the virus and prevent drug resistance?[J].AntivirChem Chemother,2004,15(6):299-305.
  • 9GHANY M,LUTCHMAN G,KLEINER D.Lamivudineand adefovir versus adefovir alone forhbeag-positive chronichepatitis B[J].Hepatology,2005,42(4Suppl 1):591A.
  • 10STOOP J N, VAN DER MOLEN R G, KUIPERS E J, et al. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B[J]. Virology, 2007, 361(1): 141-148.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部